Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.65M$17.65Mderived+3.8% vs Q4 2023 Net Income-$9.21M-$9.21MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$11,221,000−3.5% Operating Incomederived-$8,354,000N/M Operating Cash Flowderived-$7,531,000N/M Free Cash Flowderived-$7,795,000N/M Margins · derivedGross margin63.6%−4.8 pt vs Q4 2023
Operating margin-47.3%+24.9 pt vs Q4 2023
Net margin-52.2%+23.7 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 21, 2025 · 80 d after period end